Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
Authors
Stephanie Duench
Peter Nash (ORCID: https://orcid.org/0000-0002-2571-788X)
Karim Richard Masri (ORCID: https://orcid.org/0000-0002-2178-9747)
Oliver FitzGerald (ORCID: https://orcid.org/0000-0002-6607-6070)
Mary Jane Cadatal
Philip J. Mease (ORCID: https://orcid.org/0000-0002-6620-0457)
Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
Stephanie Duench, Peter Nash, Karim Richard Masri, Oliver FitzGerald et al.
Citations
2 citations
Journal
Arthritis Research & Therapy
Topics
Rheumatoid Arthritis Research and Therapies
Field-Weighted Citation Impact (FWCI)
0.94
article
Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
Stephanie Duench, Peter Nash, Karim Richard Masri, Oliver FitzGerald, Mary Jane Cadatal, Philip J. Mease, Dafna Gladman
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
Arthritis Research & TherapyVol. 26(1)
Institutions
University College Dublin (IE), Griffith University (AU), Pfizer (United States) (US), University of Toronto (CA), Providence College (US), University of Washington (US), Toronto Western Hospital (CA), Swedish Medical Center (US), Krembil Research Institute